ARTICLES
323 Genetic Counseling in Pediatrics
Quinn Stein, Rebecca Loman, Taylor Zuck
332 Disorders of the Umbilical Cord
Hemananda Muniraman, Tara Sardesai, Sneeta Sardesai
342 Vomiting in Children
T. Matthew Shields, Jenifer R. Lightdale
INDEX OF SUSPICION
359 Case 1: Microcephaly, Skeletal Dysplasia, and Immunodeficiency in a Newborn
Tarek Belal, Debra-Lynn Day-Salvatore, Janet Malcolmson
363 Case 2: 3-month-old Boy with Micropenis
Mustafa Tosur, Lefkothia P. Karaviti
366 Case 3: Skull Depression in a 9-month-old Girl
Alvaro Galvis, Anthony Shoo, Aaron R. Shedlock
370 Case 4: Recurrent Orange Urine and Abdominal Pain in a 13-year-old Boy
Josef Newman, Bhavana Kandikattu
IN BRIEFS
372 Safety: Texting while Driving
Tierra D. Burrell, Kamila B. Mistry
374 CME Quiz Clarification
CME Quiz Correction
375 SGA and VLBW Infants: Outcomes and Care
Kasey Jackson, John W. Harrington
ONLINE
e31 Visual Diagnosis: A Ring of Long, Dark, Coarse Hair on the Scalp of a 5-month-old Girl
Alexander K.C. Leung, Benjamin Barankin
Disclosures

- Philip Fischer, MD, disclosed he has received honoraria from Relias Learning (AHC Media).
- Neal LeLeiko, MD, PhD, disclosed he owns stocks/bonds in Celgene Corp. and serves as a paid consultant to AbbVie Inc. as a member of the data monitoring board of a new drug potentially of use in irritable bowel syndrome.
- E. Steve Roach, MD, receives an honorarium from Elsevier for serving as editor of *AMA PRA Category 1 Credit™ Pediatrics in Review*.
- Philip Fischer, MD, disclosed he has received honoraria from Relias Learning (AHC Media).
- Neal LeLeiko, MD, PhD, disclosed he owns stocks/bonds in Celgene Corp. and serves as a paid consultant to AbbVie Inc. as a member of the data monitoring board of a new drug potentially of use in irritable bowel syndrome.
- E. Steve Roach, MD, receives an honorarium from Elsevier for serving as editor of *AMA PRA Category 1 Credit™ Pediatrics in Review*.

Each of the editorial board members, reviewers, question writers, PREP Coordinating Committee members and staff has disclosed, if applicable, that the CME content he/she edits/writes/reviews may include discussion/reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturers. None of the editors, board members, reviewers, question writers, PREP Coordinating Committee members, or staff has any relevant financial relationships to disclose, unless noted below. The AAP has taken steps to resolve any potential conflicts of interest.

Disclosures

- Philip Fischer, MD, disclosed he has received honoraria from Relias Learning (AHC Media).
- Neal LeLeiko, MD, PhD, disclosed he owns stocks/bonds in Celgene Corp. and serves as a paid consultant to AbbVie Inc. as a member of the data monitoring board of a new drug potentially of use in irritable bowel syndrome.
- E. Steve Roach, MD, receives an honorarium from Elsevier for serving as editor of *Pediatric Neurology*.
- Miriam Weinstein, MD, is a paid consultant participating on the ad boards: for a new topical eczema product for Pfizer Inc.; and for a systemic eczema therapy for Amgen Inc.
- The journal extends special thanks to the following question writers and ancillary reviewers who contributed to this issue:

  - Philip Campion, MD
  - Courtney Wusthoff, MD
  - Ana Creo, MD
  - Stephanie Stan, MD
  - Doug Selcen, MD

*Pediatrics in Review* offers 36 CME articles per year. A maximum of one *AMA PRA Category 1 Credit™* is earned after achieving a 60% score on each designated quiz.

2018 *Pediatrics in Review* is approved for a total of 30 Maintenance of Certification (MOC) Part 2 credits by the American Board of Pediatrics through the AAP MOC Portfolio Program.

**CME STATEMENTS:**

The American Academy of Pediatrics (AAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAP designates this journal-based CME activity for a maximum of 1.00 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is acceptable for a maximum of 1.00 AAP credit. These credits can be applied toward the AAP CME/CPD* Award available to Fellows and Candidate Members of the AAP.

The American Academy of Physician Assistants accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.00 hour of Category 1 credit for completing this program.

This program is approved for 1.00 NAPNAP CE contact hour; pharmacology (PO) and psychopharmacology contact hours to be determined per the National Association of Pediatric Nurse Practitioners (NAPNAP) Continuing Education Guidelines.

It has been established that each CME activity will take the learner approximately 1 hour to complete.

*Continuing Professional Development*

**How to complete this activity:**

*Pediatrics in Review* can be accessed and reviewed in print or online at http://pedsinreview.aappublications.org. Learners can claim credit monthly online upon completion of each CME article. The deadline for completing this activity is December 31, 2020. Credit will be recorded in the year in which it is submitted. It is estimated that it will take approximately 1 hour to complete each CME article. This activity is not considered to have been completed until the learner documents participation in that activity to the provider via online submission of answers. Course evaluations are online.

**MOC STATEMENT:**

This activity is approved for 30.00 points of MOC Part 2 credit by the American Board of Pediatrics. All approved activities must be completed by the MOC Credit Approval End Date. All deadlines and MOC point values should be confirmed by checking the ABP Activity Catalog within each physician’s ABP Portfolio.